Abbisko Cayman Limited (HK:2256) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Abbisko Cayman Limited’s subsidiary, Abbisko Therapeutics, has received approval from China’s Center for Drug Evaluation to begin a critical clinical study for irpagratinib, a promising new treatment for advanced hepatocellular carcinoma. This study aims to establish irpagratinib’s efficacy, potentially making it the first FGFR4 inhibitor available for patients with FGF19 overexpression, a condition that affects about 30% of HCC patients worldwide. Such advancements could herald a pivotal shift in treatment options for this challenging cancer type.
For further insights into HK:2256 stock, check out TipRanks’ Stock Analysis page.